CONCLUSION: From a genetic perspective, this study finds that Metformin may reduce the risk of NEU and BID while increasing the risk of ADHD and INS. These findings not only provide theoretical support for further research into the etiological mechanisms but also offer valuable reference points for the clinical use of Metformin in treating NEU and BID, and for exercising caution in its use among patients with ADHD and INS.
